Total Funding
70
54
Total FundingSeries C raised
Growth Score
-13 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
34736
4TEEN4 Pharmaceuticals develops innovative therapies and biomarkers for diagnosis, prediction, and treatment of Circulatory Shock.
- Andreas Bergmann: Chief Executive Officer
About the Company
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a first in class antibody therapy targeting circulating Dipeptidyl Peptidase 3 (cDPP3), a validated biotarget for the treatment of Circulatory Shock. 4TEEN4 Pharmaceuticals GmbH developed and out-licenses a DPP3 assay, for prediction and stratification of patients in
danger of entering into Circulatory Shock
